BMS to present new data at AASLD annual Meeting

StephenW

http://www.marketwatch.com/story/bristol-myers-squibb-to-present-new-data-demonstrating-companys-leadership-in-liver-disease-at-the-liver-meetingr-aasld-annual-meeting-2011-09-30
Bristol-Myers Squibb to Present New Data Demonstrating Company's Leadership in Liver Disease at The Liver Meeting(R) / AASLD Annual Meeting                                Oral presentation on BARACLUDE(R) (entecavir) reinforces continued clinical development commitment in hepatitis B施贵宝公司的领导在肝病肝会议
/肝病学会年度会议提出新的数据表明对BARACLUDE(R)恩替卡韦）的口头陈述,
加强继续在B型肝炎的临床发展的承诺


Abstract Number   Title                                                                              Date/Time  
---------------          --------------------------------------------------------------------   ------------------------
Hepatitis B: BARACLUDE Clinical Data
------------------------------------------------------------------------------------------------------------------
Oral              Entecavir (ETV) monotherapy for 96 weeks is comparable to              Presidential Plenary III
#223              combination therapy with ETV plus tenofovir (TDF) in                        Nov. 8
                      nucleos(t)ide-naive patients with chronic hepatitis B (CHB): the        8:00 am PST
                     BE-LOW study
---------------   --------------------------------------------------------------------   ------------------------
Hepatitis B: Outcomes Research / Real-World Data     ------------------------------------------------------------------------------------------------------------------
       Poster      Real World Data on Long Term Treatment Initiation in patients with       Nov. 5
        #458       Chronic Hepatitis B: cohort observations in France, Germany, Poland,  
                       Romania and Turkey
        ---------------   --------------------------------------------------------------------   ------------------------
       Poster      Cost-effectiveness of entecavir versus adefovir for the treatment of       Nov. 5
       #478       chronic hepatitis B in patients with decompensated cirrhosis  
      ---------------   --------------------------------------------------------------------   ------------------------
        Poster     Treatment Patterns, Health Care Use, and Costs associated with         Nov. 5
       #481         First-Line Treatment for Chronic Hepatitis B with Entecavir versus
                          Tenofovir
       ---------------   --------------------------------------------------------------------   ------------------------
       Poster       Treatment Patterns, Health Care Use, and Costs associated with         Nov. 5
       #482         First-Line Treatment for Chronic Hepatitis B with Oral Antivirals
                        Recommended by Current Guidelines versus Oral Antivirals Not  
                        Recommended by Current Guidelines